Using a CD28 and CD117 gating strategy, we determined that ILC3s, the primary secretors of IL-22 and IL-17, were present at twice the frequency in subject 1 blood samples taken before CTLA4-Ig therapy than were present in HD samples (Figure 4E). This evidence concerns the gene IL22 and Huntington disease.